Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Chewable Lipitor obtains European approval for use in children

July 8, 2010

ZP-2929 shows promise in preclinical models of obesity and type 2 diabetes

July 7, 2010

Corcept begins dosing in phase III study of Corlux in Cushing's syndrome

July 6, 2010

BioSante reports results from phase II study of its Pill-Plus oral contraceptive

July 6, 2010

Pfizer claims cholecystokinin-1 agonists for obesity and co-morbidities

July 6, 2010

Sanofi-aventis and JDRF partner for type 1 diabetes therapeutics

July 5, 2010

GPR119 agonist AS-1535907 regulates insulin expression and pancreatic beta-cell mass in vivo

July 5, 2010

Euroscreen claims new GPR43 agonists/partial agonists

July 5, 2010

Eisai to market lorcaserin for obesity and weight management in the U.S.

July 2, 2010

Endo submits complete response to FDA regarding NDA for Fortesta

July 2, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...